Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind active-controlled study of avatrombopag vs eltrombopag in chronic immune thrombocytopenia
2011-000831-10Phase 3Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of avatrombopag in immune thrombocytopenic purpura (ITP) and Thrombocytopenia (2 arms), sponsored by Eisai Co., Ltd. Started May 2012; status: terminated.
02
Drugs
avatrombopag
03
Conditions
immune thrombocytopenic purpura (ITP)Thrombocytopenia
Beyond the preview
Go deeper on 2011-000831-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000831-10.